tocilizumab IV
Selected indexed studies
- Trial of Tocilizumab in Giant-Cell Arteritis. (N Engl J Med, 2017) [PMID:28745999]
- Tocilizumab: A Review in Rheumatoid Arthritis. (Drugs, 2017) [PMID:29094311]
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. (Ann Rheum Dis, 2023) [PMID:36357155]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters. (2021) pubmed
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. (2023) pubmed
- Trial of Tocilizumab in Giant-Cell Arteritis. (2017) pubmed
- Tocilizumab: A Review in Rheumatoid Arthritis. (2017) pubmed
- The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. (2021) pubmed
- Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. (2022) pubmed
- International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. (2021) pubmed
- Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. (2019) pubmed
- Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults. (2022) pubmed
- Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. (2021) pubmed